High‐Grade Atypia in Circulating Tumour‐Related Endothelial‐Like Cells Serves as a Specific Marker for Malignant Thoracic Tumours
Cytopathology · 2026-07 · 37 (4) · 344-352
DOI: 10.1111/cyt.70075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytopathology, online erschienen am 08.04.2026. Verfasst von Noriyoshi Sawabata und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Kawanishi City Medical Center, Kawanishi, Hyogo, Japan. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Biomarkers, Tumor, Endothelial Cells, Thoracic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Objective
Conventional liquid biopsy primarily focuses on epithelial circulating tumour cells (CTCs). We previously demonstrated that a population of circulating cells in thoracic tumours express the vascular endothelial marker ERG. In this study, we defined these ERG‐positive cells with endothelial morphology in liquid‐based cytology (LBC) as “circulating tumor‐related endothelial‐like cells” (CELCs). Our aim was to establish a morphological grading system to distinguish malignancy‐specific High‐Grade CELC from benign or reactive CELC populations.
Methods
Preoperative arterial blood samples from 28 patients (25 malignant and 3 benign cases) were processed using a soft‐microporous filtration system (S‐MPF). Captured cells were evaluated by Papanicolaou staining. CELCs were categorized based on LBC morphology into “Low‐Grade” (single cells or clusters < 15 cells) and “High‐Grade” (three‐dimensional morula‐like clusters ≥ 15 cells with marked nuclear pleomorphism).
Results
CELCs were identified in 13 cases (46.4%). While Low‐Grade CELCs were observed in both cohorts (12 malignant, 1 benign), High‐Grade clusters—representing definitive CTEC signatures—were exclusively identified in 8 malignant cases (5 primary lung cancers, 2 metastatic tumours, and 1 thymic cancer). No High‐Grade features were detected in benign lesions, yielding a specificity of 100% (95% CI: 29.2%–100%) for malignancy.
Conclusion
Implementing an LBC‐based morphological threshold of ≥ 15 cells allows malignancy‐specific CELCs to be accurately distinguished from the broader population of CELCs. This grading system provides a practical and highly specific liquid biopsy framework, ensuring precise identification of tumour‐associated endothelial clusters even amidst reactive non‐malignant cells. Trial Registration UMIN Clinical Trials Registry (UMIN‐CTR, identifier: UMIN000058385)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Kawanishi City Medical Center, Kawanishi, Hyogo, Japan.
- Department of Diagnostic Pathology, Nara Medical University, Nara, Japan.
- Department of Thoracic Surgery, Minoh City Hospital, Minoh, Japan.
- Department of Hospital-Based Pathology, Nara Medical University Hospital, Nara, Japan.
- Faculty of Health Care Department of Clinical Laboratory Science, Tenri University, Nara, Japan.
- Department of Diagnostic Pathology, Kawanishi City Medical Center, Kawanishi, Hyogo, Japan.
ORCID-Profile: Noriyoshi Sawabata
Förderung
- JSPS KAKENHI
Zitieren
APA
Sawabata, N., Hashimoto, N., Nakane, S., Tatsumi, S., Nishikawa, T., & Ito, T. (2026). High‐Grade Atypia in Circulating Tumour‐Related Endothelial‐Like Cells Serves as a Specific Marker for Malignant Thoracic Tumours. Cytopathology, 37(4), 344-352. https://doi.org/10.1111/cyt.70075
Vancouver
Sawabata N, Hashimoto N, Nakane S, Tatsumi S, Nishikawa T, Ito T. High‐Grade Atypia in Circulating Tumour‐Related Endothelial‐Like Cells Serves as a Specific Marker for Malignant Thoracic Tumours. Cytopathology. 2026;37(4):344-352. doi:10.1111/cyt.70075
BibTeX
@article{Sawabata2026,
author = {Sawabata, Noriyoshi and Hashimoto, Nagisa and Nakane, Shigeru and Tatsumi, Shigenobu and Nishikawa, Takeshi and Ito, Takashi},
title = {High‐Grade Atypia in Circulating Tumour‐Related Endothelial‐Like Cells Serves as a Specific Marker for Malignant Thoracic Tumours},
journal = {Cytopathology},
year = {2026},
volume = {37},
number = {4},
pages = {344--352},
doi = {10.1111/cyt.70075}
}
EUVIMED